US 12,409,249 B2
Compositions and methods for immune tolerance
Sangeeta N. Bhatia, Lexington, MA (US); Arnav Chhabra, Cambridge, MA (US); and Marcela V. Maus, Lexington, MA (US)
Assigned to Massachusetts Institute of Technology, Cambridge, MA (US); and The General Hospital Corporation, Boston, MA (US)
Filed by Massachusetts Institute of Technology, Cambridge, MA (US); and The General Hospital Corporation, Boston, MA (US)
Filed on Nov. 26, 2019, as Appl. No. 16/696,947.
Claims priority of provisional application 62/873,017, filed on Jul. 11, 2019.
Claims priority of provisional application 62/771,457, filed on Nov. 26, 2018.
Prior Publication US 2020/0164105 A1, May 28, 2020
Int. Cl. A61L 27/36 (2006.01); A61K 35/12 (2015.01); A61K 35/33 (2015.01); A61K 35/407 (2015.01); A61K 35/44 (2015.01); A61L 27/22 (2006.01); A61L 27/38 (2006.01); A61L 27/52 (2006.01); C12N 5/071 (2010.01); C12N 5/077 (2010.01)
CPC A61L 27/3604 (2013.01) [A61K 35/33 (2013.01); A61K 35/407 (2013.01); A61K 35/44 (2013.01); A61L 27/225 (2013.01); A61L 27/3683 (2013.01); A61L 27/3804 (2013.01); A61L 27/3808 (2013.01); A61L 27/3886 (2013.01); A61L 27/52 (2013.01); C12N 5/0656 (2013.01); C12N 5/067 (2013.01); C12N 5/069 (2013.01); A61K 2035/122 (2013.01); A61L 2430/40 (2013.01); C12N 2502/1323 (2013.01); C12N 2502/14 (2013.01); C12N 2502/28 (2013.01); C12N 2510/00 (2013.01); C12N 2533/56 (2013.01)] 21 Claims
 
1. A composition suitable for implantation into a subject comprising:
(a) a first cell population comprising parenchymal cells, endothelial cells, or a combination thereof, wherein the first cell population is allogenic to the subject and is not genetically engineered; and
(b) a second cell population comprising stromal cells genetically engineered to express at least one immune checkpoint protein, which inhibit an immune response to the first cell population following implantation of the composition into the subject, wherein the at least one immune checkpoint protein is PD-L1, and wherein the stromal cells are not genetically engineered to express CTLA4.